Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: This study aimed to compare the clinical oral health status of individuals with Methamphetamine (MA), Cannabis (THC), and Polysubstance (PS) use disorders to healthy controls, and assess the impact of substance type, usage duration, quantity, and oral health behaviors on dental health outcomes through comprehensive oral examinations.
Methods: This cross-sectional clinical study was conducted at İzmir Democracy University Buca Seyfi Demirsoy Education and Research Hospital between April 2024 and August 2024. A total of 190 individuals with substance use disorders (MA, THC, and PS users) and 91 healthy controls participated. Sociodemographic data, substance use history, and oral health behaviors were collected using a researcher-developed questionnaire and the Turkish version of the Hiroshima University Dental Behavior Inventory (HU-DBI). Oral health status was assessed through clinical oral examinations using the Decayed, Missing, and Filled Teeth (DMFT) index. Statistical analyses were performed using SPSS 26.0, applying t-tests, ANOVA, Chi-square tests, and Pearson correlation to evaluate group differences and relationships between variables. A p-value of < 0.05 was considered statistically significant.
Results: The study revealed significant differences in oral health among substance users compared to the control group. MA users had the highest DMFT scores (11.04 ± 5.56), followed by THC users (9.49 ± 5.87), and PS users (8.40 ± 4.52), with the control group showing the lowest scores (6.08 ± 4.18) (p<0.001). The study also found a moderate positive correlation between MA use and DMFT scores, indicating that longer and higher usage leads to poorer oral health, while no significant association was observed between THC use and DMFT scores. Additionally, significant disparities in education levels were observed, with substance users having lower education compared to controls (p=0.001). HU-DBI scores indicated poorer oral health behaviors in substance users, though the difference was not statistically significant (p=0.053).
Discussion: The study reveals that all substance use groups, including MA, THC, and PS users, exhibit significantly poorer oral health outcomes, with higher DMFT scores and worse oral health behaviors compared to the control group, highlighting the critical need for comprehensive dental care interventions for individuals with substance use disorders.
Clinical Trial Registration: https://clinicaltrials.gov/study/NCT06640712, identifier NCT06640712.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825756 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2025.1510228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.
JAMA Pediatr
September 2025
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Importance: For the first time in nearly 2 decades, the US infant mortality rate has increased, coinciding with a rise in overdose-related deaths as a leading cause of pregnancy-associated mortality in some states. Prematurity and low birth weight-often linked to opioid use in pregnancy-are major contributors.
Objective: To assess the health and economic impact of perinatal opioid use disorder (OUD) treatment on maternal and postpartum health, infant health in the first year of life, and infant long-term health.
Impact of Alcohol Consumption on Selected Cancer Incidence Trends Among Adults in the United States, 2008-2019.
Cancer Epidemiol Biomarkers Prev
September 2025
National Cancer Institute, Bethesda, MD, United States.
Background: Alcohol consumption is a risk factor for certain cancers and is increasing in the United States. We estimated the impact of alcohol consumption on cancer incidence trends in the United States from 2008-2019 across six alcohol-related cancers among men and women.
Methods: Average daily alcohol consumption (ADC) was calculated from the National Health Interview Survey (NHIS, 1998-2009) and adjusted to per capita sales data to account for underreporting alcohol use.
Salivary interleukin-17A and interleukin-18 as potential biomarkers of immunopathogenesis and oral health status in rheumatoid arthritis.
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Dentistry, Al-Esraa University, Baghdad, Iraq.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and is often associated with poor oral health. Cytokines play a central role in RA immunopathogenesis. This case-control study investigated the involvement of salivary interleukin-17A (IL-17A) and interleukin-18 (IL-18) in RA patients in relation to oral health status.
View Article and Find Full Text PDFDesign of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDF